EUROGIN
INTERNATIONAL MULTIDISCIPLINARY HPV CONGRESS
Accelerating detection and elimination of HPV and related cancers

April 10-12, 2022
Congress Center
Düsseldorf, Germany



CERVICAL NEOPLASIA

EFFICACY OF A MULTI-INGREDIENT *CORIOLUS VERSICOLOR*-BASED VAGINAL GEL IN HIGH-RISK HPV INFECTED PATIENTS: RESULTS OF 6 DIFFERENT STUDIES

Authors:
Cortés J[1], Dexeus D[2], Palacios S[3], Serrano L[4], Gajino C[5], Marín E[6], Criscuolo A[7], Riera M[8], Gaslain Y[9]
[1]Private Practice, Palma, Spain, [2]Clínica Ginecológica Women's, Barcelona, Spain, [3]Instituto Palacios de Salud y Medicina de la Mujer, Madrid, Spain, [4]Policlínico HM Gabinete Velázquez, Madrid, Spain, [5]Hospital Materno Infantil Teresa Herrera, A Coruña, Spain, [6]Hospital Álvaro Cunqueiro, Vigo, Spain, [7]Tor Vergata University Hospital, Rome, Italy, [8]Institut Català de la Salut, Barcelona, Spain, [9]Procare Health Iberia, Barcelona, Spain

INTRODUCTION:

Papilocare® is a patented multi-ingredient vaginal gel which includes *Coriolus versicolor* and other active ingredients. It is approved in Europe with the indication of re-epitelization for the cervical transformation zone for the prevention and co-adjuvant treatment of HPV-induced lesions.

OBJECTIVES:

The main objective is to evaluate the consistency of the efficacy of a multi-ingredient *Coriolus versicolor*-based vaginal gel on high-risk HPV (HR-HPV) clearance in 6 different studies.

METHODS:

Results from 4 independent observational studies (6 month-treatment period with Papilocare®) were compared to results from a randomized, open, parallel, controlled trial (Paloma: NCT04002154) and an observational, multicenter, prospective, one-cohort study (PapilOBS: NCT04199260).

- **Vigo study:** Prospective one-cohort. Secondary endpoint (SE), HPV clearance in 86 patients infected by HPV 16 and/or 18.
- **Coruña study:** Retrospective one-cohort. Primary endpoint (PE), HR-HPV clearance assessed in 86 medical patients' records.
- **Hospitalet study:** Retrospective one-cohort. PE, Composite efficacy variable (patients with normal cytology and/or HPV clearance) in 91 HR-HPV patients.
- **Roma study**: Retrospective controlled. PE, HR-HPV clearance in 183 patients.
- **Paloma trial:** SE, HR-HPV clearance in 91 patients.
- **PapilOBS study:** SE, HR-HPV clearance in 192 patients.

RESULTS:

48% of patients cleared 16-/18 -HPV in Vigo study. 58% of reduction was observed in the number of HR-HPV patients (Coruña) and 72.5% normalized cytology and/or cleared HR-HPV (Hospitalet). 67% HR-HPV clearance was observed (treated group) vs 37.2% (control group), in the Roma study. In the Paloma trial, HR-HPV clearance reached 63% (treated group) vs 40% (control group). 57.4% HR-HPV clearance was observed in the PapilOBS study.

HR-HPV CLEARANCE AT 6 MONTHS RESULTS IN DIFFERENTS STUDIES



CONCLUSION:

Papilocare® has shown significant consistent rates of efficacy with a 64% of HR-HPV clearance in weighted average in 6 different studies involving more than 700 patients. These data reinforce the beneficial effect observed in HR-HPV patients.